2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[2-fluoro-5-[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-

T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson's disease and related disorders research[1].

T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson’s disease and related disorders research[1]. T0467 (2.5-20 μM; 3 hours) stimulates the mitochondrial translocation of GFP-Parkinover 12 μM in HeLa/GFP-Parkin cells[1]. When HeLa/GFP-Parkin cells are treated with 20 μM T0467 for 3 h, GTP-Parkin is translocated to the mitochondria in approximately 21% of cells[1].T0467 does not show obvious toxicity in Drosophila at concentrations Drosophila larval muscles[1].

[1]. Kahori Shiba-Fukushima, et al. A Cell-Based High-Throughput Screening Identified Two Compounds that Enhance PINK1-Parkin Signaling. iScience. 2020 May 22;23(5):101048.